ATE550426T1 - Polypeptide zur auslösung einer immunreaktion gegen krebs - Google Patents

Polypeptide zur auslösung einer immunreaktion gegen krebs

Info

Publication number
ATE550426T1
ATE550426T1 AT07105178T AT07105178T ATE550426T1 AT E550426 T1 ATE550426 T1 AT E550426T1 AT 07105178 T AT07105178 T AT 07105178T AT 07105178 T AT07105178 T AT 07105178T AT E550426 T1 ATE550426 T1 AT E550426T1
Authority
AT
Austria
Prior art keywords
polypeptides
against cancer
triggering
immune response
response against
Prior art date
Application number
AT07105178T
Other languages
English (en)
Inventor
Gustav Gaudernack
Stein Seboe-Larssen
Mona Moller
Jon Amund Eriksen
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9905720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE550426(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gemvax As filed Critical Gemvax As
Application granted granted Critical
Publication of ATE550426T1 publication Critical patent/ATE550426T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
AT07105178T 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs ATE550426T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0031430.2A GB0031430D0 (en) 2000-12-22 2000-12-22 Polypeptides

Publications (1)

Publication Number Publication Date
ATE550426T1 true ATE550426T1 (de) 2012-04-15

Family

ID=9905720

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07105178T ATE550426T1 (de) 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs
AT01272392T ATE358716T1 (de) 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01272392T ATE358716T1 (de) 2000-12-22 2001-12-18 Polypeptide zur auslösung einer immunreaktion gegen krebs

Country Status (14)

Country Link
US (4) US7078416B2 (de)
EP (3) EP1862544B2 (de)
JP (3) JP2004522433A (de)
AT (2) ATE550426T1 (de)
AU (3) AU2002216477B2 (de)
CA (2) CA2432971C (de)
CY (2) CY1106564T1 (de)
DE (1) DE60127715T2 (de)
DK (3) DK1862544T3 (de)
ES (2) ES2280311T3 (de)
GB (1) GB0031430D0 (de)
NO (2) NO332137B1 (de)
PT (2) PT1352056E (de)
WO (1) WO2002051994A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1581174B1 (de) * 2002-12-16 2018-04-25 GlobeImmune, Inc. Impfstoffe auf hefebasis als immuntherapie
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
ES2527946T3 (es) 2003-03-05 2015-02-02 Dendreon Corporation Composiciones y métodos que emplean polipéptidos de marco de lectura alternativa para el tratamiento de cáncer y enfermedades infecciosas
WO2006044923A2 (en) * 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
CN110709094A (zh) 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
IL133830A0 (en) * 1997-07-01 2001-04-30 Cambia Biosystems Llc Vertebrate tolomerase genes and proteins and uses thereof
EP0987789A4 (de) * 1998-03-31 2004-09-22 Matsushita Electric Ind Co Ltd Antenne und digitaler fernsehempfänger
JP2002509716A (ja) * 1998-03-31 2002-04-02 ユニバーシティ テクノロジー コーポレイション テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
EP1171612A2 (de) 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-spezifisches krebsimpfstoff
JP2003518364A (ja) 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
DK1862544T3 (da) 2012-07-09
AU2007211889A1 (en) 2007-09-13
US20120269858A1 (en) 2012-10-25
PT1862544E (pt) 2012-05-07
NO20032818D0 (no) 2003-06-19
NO342257B1 (no) 2018-04-30
WO2002051994A8 (en) 2003-03-06
AU2002216477C1 (en) 2002-07-08
DK1352056T3 (da) 2007-05-29
EP1862544B1 (de) 2012-03-21
US20060194731A1 (en) 2006-08-31
NO20032818L (no) 2003-08-21
AU2010200620B2 (en) 2012-11-01
US7375117B2 (en) 2008-05-20
DK2361978T3 (en) 2016-01-25
US7078416B2 (en) 2006-07-18
WO2002051994A2 (en) 2002-07-04
US8193326B2 (en) 2012-06-05
ES2382821T3 (es) 2012-06-13
NO332137B1 (no) 2012-07-02
DE60127715D1 (de) 2007-05-16
AU2007211889B2 (en) 2009-11-19
AU2007211889B8 (en) 2009-12-10
WO2002051994A3 (en) 2002-12-27
ES2280311T3 (es) 2007-09-16
AU2007211889C1 (en) 2010-06-10
EP1862544B2 (de) 2016-03-09
CA2432971C (en) 2012-09-04
JP2012080883A (ja) 2012-04-26
EP1352056B1 (de) 2007-04-04
PT1352056E (pt) 2007-05-31
JP2014138587A (ja) 2014-07-31
CY1112735T1 (el) 2016-02-10
EP1352056A2 (de) 2003-10-15
JP2004522433A (ja) 2004-07-29
AU2010200620A1 (en) 2010-03-11
ATE358716T1 (de) 2007-04-15
GB0031430D0 (en) 2001-02-07
CA2782510A1 (en) 2002-07-04
US20080187551A1 (en) 2008-08-07
AU2002216477B2 (en) 2007-05-24
CA2432971A1 (en) 2002-07-04
US20040072759A1 (en) 2004-04-15
CY1106564T1 (el) 2012-01-25
DE60127715T2 (de) 2007-12-27
EP2361978B1 (de) 2015-10-14
EP1862544A1 (de) 2007-12-05
CA2782510C (en) 2014-07-15
EP2361978A1 (de) 2011-08-31
NO20110429L (no) 2003-08-21

Similar Documents

Publication Publication Date Title
NO20110429L (no) Polypeptider og nukleinsyre-DNA for anvendelse innen medisin
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
ATE315088T1 (de) Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
WO2002080851A3 (en) Chimeric vaccines
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
HK1053985A1 (zh) 人類多肽引起或導致殺死細胞，包括淋巴腫瘤細胞
WO1997048370A3 (en) Vaccines comprising synthetic genes
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
AU5810201A (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO2005007673A3 (en) Immunogenic peptides
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
WO2003093298A3 (en) Immunogenic peptides
UY26588A1 (es) Mutantes de ehv gm-negativos
AU1572702A (en) Novel immunomodulatory protein and useful embodiments thereof
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof